news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

1. Zhejiang News:

1. On July 15, the Zhejiang Cultural Research Project's major project "Zhejiang Calligraphy Series" was launched for the first time.

2. The 9th Standing Committee of the Shaoxing Municipal People's Congress held its 21st meeting on July 15 and accepted Comrade Shi Huifang's request to resign from the post of Mayor of Shaoxing. It was decided that Comrade Wu Dengfen would serve as Deputy Mayor and Acting Mayor of Shaoxing.

3. In the first half of this year, Zhejiang's industrial electricity consumption increased by 8.54% year-on-year. Among them, the electricity consumption of manufacturing industry increased by 10.45% year-on-year, accounting for 84.97% of industrial electricity consumption. More than 60% of the 31 sub-sectors of the manufacturing industry achieved double-digit growth in electricity consumption.

2. Positive news:

Deye Technology:The cumulative deviation of the closing price increase of the company's stock exceeded 20% in three consecutive trading days on July 11, July 12, and July 15, 2024.

Intelligent Technology:The company released its performance forecast on July 15, and expects to achieve a net profit of 115 million to 135 million yuan in the first half of 2024, a year-on-year increase of 130.11% to 170.13%.

Infitec:The cumulative deviation of the closing price increase of the company's stock for three consecutive trading days on July 11, 2024, July 12, 2024, and July 15, 2024 reached 30%.

Changchuan Technology:The company released its performance forecast on July 15, and expects to achieve a net profit of 200 million to 230 million yuan in the first half of 2024, a year-on-year increase of 876.62% to 1023.12%.

Betta Pharmaceuticals:The company has received the "Notice of Approval for Drug Clinical Trials" issued by the National Medical Products Administration (Notice No.: 2024LP01566, 2024LP01567). The clinical trial application for EYP-1901 intravitreal implant for wet age-related macular degeneration (wAMD) jointly submitted by the company and EyePoint Pharmaceuticals, Inc. has been approved by the NMPA.

3. Negative news:

Tailin Bio:Mr. Xia Xinqun, a director and deputy general manager who holds 1,177,488 shares of the Company (accounting for 1.08% of the Company's total share capital), plans to reduce his holdings of the Company's shares by no more than 294,300 shares, accounting for 0.27% of the Company's total share capital, through centralized bidding transactions within three months after 15 trading days from the date of the pre-disclosure announcement of the share reduction.

Xinhua Shares:On July 15, 2024, the company received the "Explanation and Apology Statement on My Purchase and Sale of the Company's Convertible Bonds Constituting Short-term Trading" from Mr. Hu Jian, the company's director. When Mr. Hu Jian, the company's director, traded the company's convertible bonds on April 29, 2024, he mistakenly bought 200 Xinhua convertible bonds due to an operational error, and the average transaction price was 121.6748 yuan per bond. He did not discover the error and continued to sell. This error caused him to buy and sell the company's convertible bonds within six months, which violated relevant regulations and constituted short-term trading.

4. Changes in senior management:

Haixiang Pharmaceutical:Ms. Wang Xiaoyang has applied to resign from the positions of director, deputy general manager and secretary of the board of directors for personal reasons. The board of directors of the company has appointed Mr. Yao Bing, director, deputy general manager and chief financial officer of the company, to perform the duties of secretary of the board of directors.

V. Related-party transactions

Homelink Technology:The company plans to jointly establish Guangxi Zhurui Ecological Technology Co., Ltd. (tentative name, subject to final approval and registration by the market supervision and management department, hereinafter referred to as "Guangxi Zhurui") with Huanlong Industry, Industrial Investment Group, and Jianyuan Tianhua. The actual controller of Jianyuan Tianhua, the joint investor, is a natural person shareholder holding more than 5% of the company's shares. The registered capital of Guangxi Zhurui Company is RMB 200 million. Among them, Jialian Technology contributed RMB 82 million, accounting for 41%; Huanlong Industry contributed RMB 82 million, accounting for 41%; Industrial Investment Group contributed RMB 20 million, accounting for 10%; Jianyuan Tianhua contributed RMB 16 million, accounting for 8%.